10 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 17 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 10, Terminated 3, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Cold Urticaria: new trials by email Literature Review of Cold Urticaria trials Research Report on Cold Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) BLU-808, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 105 | 2025-05-28 | 2026-07-22 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Remibrutinib, Placebo - Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 44 | 2025-05-22 | 2026-09-28 |
| A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome VTX2735 - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zomagen Biosciences Ltd. | 7 | 2023-03-18 | 2025-03-10 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) ZYIL1 capsule - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zydus Lifesciences Limited | 3 | 2022-06-01 | 2022-07-11 |
| Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) DFV890 - Familial Cold Autoinflammatory Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 4 | 2021-09-20 | 2024-10-09 |
| Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) ATI-450 - Cryopyrin-Associated Periodic Syndrome | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 1 | 2020-10-23 | 2023-09-21 |
| A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS) Tranilast - Cryopyrin-Associated Periodic Syndromes | Phase 2 | Unknown | Peking Union Medical College Hospital | 71 | 2019-05-23 | 2019-06-04 |
| HL2351 CAPS Phase II Study HL2351 - Cryopyrin-Associated Periodic Syndromes (CAPS) | Phase 2 | Terminated | Handok Inc. | 8 | 2015-10-01 | 2017-01-04 |
| Cold Contact Urticaria Treatment With Rilonacept Rilonacept, Placebo - Cold Contact Urticaria | Phase 2 | Completed | Charite University, Berlin, Germany | 20 | 2015-01-01 | 2018-07-17 |
| Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria Rupatadine - Cold Contact Urticaria | Phase 2 | Completed | Charite University, Berlin, Germany | 24 | 2012-06-01 | 2014-10-15 |
| Cold Urticaria Treatment With Xolair Omalizumab, Placebo - Cold Contact Urticaria | Phase 2 | Completed | Charite University, Berlin, Germany | 31 | 2012-04-01 | 2017-04-07 |
| Bilastine Updosing - Characterization of Underlying Mechanisms Bilastine - Cold Contact Urticaria | Phase 2 / Phase 3 | Completed | Charite University, Berlin, Germany | 20 | 2010-09-01 | 2012-05-31 |
| A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease XOMA 052 - Muckle Wells Syndrome, Autoinflammatory | Phase 1 / Phase 2 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2010-08-27 | 2017-07-02 | |
| Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) rilonacept - Muckle-Wells Syndrome, Schnitzler Syndrome | Phase 2 | Completed | Charite University, Berlin, Germany | 10 | 2009-01-01 | 2012-05-31 |
| Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms canakinumab - NALP3 Mutation | Phase 2 | Completed | Novartis Pharmaceuticals | 34 | 2005-01-01 | 2009-02-17 |
| Interleukin-1 Trap to Treat Autoinflammatory Diseases IL-1 Trap - Inflammation, Familial Mediterranean Fever | Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 11 | 2004-10-01 | 2014-03-04 |
| Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease anakinra - Nervous System Malformations, Arthropathy, Neurogenic | Phase 1 / Phase 2 | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 43 | 2003-09-01 | 2016-12-01 |
Cryopyrin-Associated Periodic Syndromes (11) · Chronic Inducible Urticaria (2) · Chronic Urticaria (2) · Familial dermographism (2) · Urticaria (2) · Arthropathy, Neurogenic (1) · Behcet Syndrome (1) · Congenital Abnormalities (1) · Familial Mediterranean Fever (1) · Fever (1) · Inflammation (1) · Joint Diseases (1) · Nervous System Malformations (1) · Papilledema (1)
Hypersensitivity (17) · Hypersensitivity, Immediate (17) · Immune System Diseases (17) · Skin Diseases (17) · Skin Diseases, Vascular (17) · Skin and Connective Tissue Diseases (17) · Urticaria (15) · Chronic Disease (13) · Disease Attributes (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Chronic Inducible Urticaria (11) · Chronic Urticaria (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)
rilonacept (3) · Interleukin 1 Receptor Antagonist Protein (1) · Omalizumab (1) · ZYIL1 (1) · bilastine (1) · canakinumab (1) · gevokizumab (1) · remibrutinib (1) · rupatadine (1) · tranilast (1)
Charite University, Berlin, Germany (5) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Novartis Pharmaceuticals (3) · Aclaris Therapeutics, Inc. (1) · Blueprint Medicines Corporation (1) · Handok Inc. (1) · Peking Union Medical College Hospital (1) · Zomagen Biosciences Ltd. (1) · Zydus Lifesciences Limited (1)
Germany (9) · United States (8) · France (3) · Spain (3) · Australia (1) · China (1) · Denmark (1) · India (1) · Italy (1) · Poland (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Karoline Krause, MD (2) · Marcus Maurer, MD (2) · David Gordon (1) · Dr Deven Parmar, MD (1) · Henrik Sonnergren, MD, PhD (1) · Hongmei Song (1) · Martin Metz, MD (1) · Raphaela T Goldbach-Mansky, M.D. (1)
PMID 16899778, PMID 18668591, PMID 21356079, PMID 22294344, PMID 22583335, PMID 25223501, PMID 27143789, PMID 28118536, PMID 28389393, PMID 36973954
ZIAAR041138-08 (1)